Geneoscopy

Geneoscopy is developing a broad range of non-invasive gastrointestinal-related diagnostic products, supported by advanced research in computational biology. Its lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas. The device received Breakthrough Device Designation from the U.S. FDA for its ability to reduce morbidity associated with colorectal cancer through advanced adenoma detection. Initial trials indicate that this diagnostic method can detect these lesions at a faster rate compared to all existing non-invasive screening tests. Geneoscopy has initiated the CRC-PREVENT trial, a 10,000-patient study aimed at evaluating the performance of its RNA-FIT stool test in detecting colorectal cancer and advanced adenomas.